Immunocore (IMCR.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Nov13

TD Cowen and H.C. Wainwright Maintain Buy Rating on Immunocore Holdings

22:52

Nov7

Immunocore Announces Encouraging Phase 1 Results for Hepatitis B Candidate IMC-I109V

13:00

Immunocore released FY2025 9 Months Earnings on November 6 (EST), actual revenue USD 295.54 M, actual EPS USD -0.1083

04:00

Immunocore released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 103.69 M (forecast USD 101.83 M), actual EPS USD -0.0035 (forecast USD -0.2475)

04:00

Aug7

Immunocore Presents Innovative Immune Modulating Drugs

13:55

Immunocore released FY2025 Semi-Annual earnings on August 7 Pre-Market EST, actual revenue USD 191.85 M, actual EPS USD -0.1051

13:30

Schedules & Filings

Schedules

Filings

Nov6

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 103.69 M, Net Income -177 K, EPS -0.0035

Aug7

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 97.96 M, Net Income -10.3 M, EPS -0.2047

May7

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 93.88 M, Net Income 5.023 M, EPS 0.1

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change